DR-270 Therapy resistance mechamisms in uterine cancers
- Algoritmes
- Behandeling op maat
- Betaaltitel
- Biomarker
- cfDNA
- DNA
- Educatie
- Geen onderdeel van een categorie
- GENAYA project
- Hartwig Medical Database
- Hartwig Medical Foundation
- Hergebruik data
- Innovatie
- IT
- Kwaliteit
- Lab proces
- Lerend zorgsysteem
- Medicijn
- Moleculaire diagnostiek
- OncoAct
- Onderzoek
- Participerende ziekenhuizen
- Pipeline
- Preventie
- Primaire Tumor Onbekend
- Uitbehandeld
- Verhalen patiënten
- Werken in de cloud
- Wetenschappelijke publicaties
- Whole genome sequencing
- Zeldzame kankers
DR-270 Therapy resistance mechamisms in uterine cancers
This project will focus on treatment resistance mechanisms in uterine cancers to develop novel targeted treatments as adjuvants or combination …
DR-266 Tumor genotype and the risk of cancer-associated venous thromboembolism: results from 4000 cancer biopsies (PANDORA study)
Venous thromboembolism (VTE), a venous blood clot, frequently occurs in cancer patients, and substantially affects morbidity, quality of life, and …
DR-265 Identification of extrachromosomal DNA-driven Mutational Processes Operating in Tumor Metastasis
Summary = Previous efforts in cancer research have been dedicated to identifying genetic alterations on the linear form of DNA, …
DR-263 Whole-genome mutational patterns
Mutations are generated by endogenous (replication errors) and exogenous processes (UV light). Studying the mutational patterns observed across both genes …
DR-260 Variation in mutational processes across the human genome
Cancer is a disease of the genome. Random factors, environmental exposures and also certain biological mechanisms have the potential to …
DR-258 Impact of somatic mutations and prostate cancer risk SNPs on enhancer activity, interpatient heterogeneity and responsive gene expression in metastatic prostate cancer
We have previously mapped in metastatic prostate cancer how genes are being regulated. Now, we aim to combine these results …
DR-257 Somatic mutations and germline variants at Estrogen Receptor / DNA binding sites and their impact on gene expression programs in metastatic breast cancer
Estrogen Receptor is a hormone-responsive protein, responsible for breast tumor growth. We found that DNA-binding specificity can predict treatment response, and …
DR-256 Altered genomic landscape of ER alpha in endometrium tumor
Endometrium cancer is one of the most common gynecological cancer and accounts for ~6% of all cancers in women. The …
DR-255 Mutational imprints of endogenous DNA damage
DNA carries the instructions to life but is also constantly damaged, causing mutation and disease. Sunlight and cigarette smoke are …
DR-254 PEGASUS: pancreatic and esophagogastric cancer: improving survival and quality of life through personalized medicine
Pancreatic cancer and esophagogastric cancer are among the most deadly forms of cancer: despite intensive treatment with chemotherapy and / …
DR-253 Comprehensive analysis of mutational signatures in metastatic cancers
The DNA in human cells are continuously exposed to internal and external challenges. The purpose of this project is to …
DR-252 Prostate cancer genomic evolution and signatures of DNA damage repair deficiencies
The purpose of our project is to identify genomic signatures related to DNA damage repair (DDR) defects in advanced prostate …
Door WGS hebben we in de moleculaire diagnostiek op onze afdeling een stap gemaakt van de analyse van minder dan 100 genen naar circa 20.000 genen per patiënt. Dat levert ontzettend veel waardevolle informatie, niet alleen voor de patiënt van vandaag, maar ook voor de patiënt van de toekomst.